Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MH004 Ointment in Non-segmental Vitiligo
NCT07682506Phase 3Recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Aug 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Vitiligo comparing MH004 1.0% Ointment with MH004 Placebo (2 arms). Primary endpoint: Proportion of participants achieving at least a 75% improvement from baseline in Facial Vitiligo Area Scoring Index at 24 weeks. Started Aug 2026; status: recruiting.
02
Drugs
tofacitinib etocomil
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT07682506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07682506.